According to the NIA-AA research criteria framework, our seven participants with abnormal amyloid (A+) but normal CSF p-tau (T−) and no tau PET available are most accurately described as consistent with Alzheimer’s neuropathologic change rather than definitive progressive dysexecutive syndrome with Alzheimer’s disease. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.